FR14C0016I2 - WEST NILE VACCINE - Google Patents

WEST NILE VACCINE

Info

Publication number
FR14C0016I2
FR14C0016I2 FR14C0016C FR14C0016C FR14C0016I2 FR 14C0016 I2 FR14C0016 I2 FR 14C0016I2 FR 14C0016 C FR14C0016 C FR 14C0016C FR 14C0016 C FR14C0016 C FR 14C0016C FR 14C0016 I2 FR14C0016 I2 FR 14C0016I2
Authority
FR
France
Prior art keywords
west nile
nile vaccine
vaccine
west
nile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR14C0016C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zoetis Services LLC
Original Assignee
Zoetis W LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis W LLC filed Critical Zoetis W LLC
Publication of FR14C0016I1 publication Critical patent/FR14C0016I1/fr
Application granted granted Critical
Publication of FR14C0016I2 publication Critical patent/FR14C0016I2/en
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
FR14C0016C 2001-07-27 2014-02-21 WEST NILE VACCINE Active FR14C0016I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30833401P 2001-07-27 2001-07-27
PCT/US2002/023447 WO2003061555A2 (en) 2001-07-27 2002-07-23 West nile vaccine

Publications (2)

Publication Number Publication Date
FR14C0016I1 FR14C0016I1 (en) 2014-03-28
FR14C0016I2 true FR14C0016I2 (en) 2015-07-24

Family

ID=27613166

Family Applications (1)

Application Number Title Priority Date Filing Date
FR14C0016C Active FR14C0016I2 (en) 2001-07-27 2014-02-21 WEST NILE VACCINE

Country Status (25)

Country Link
US (8) US7153513B2 (en)
EP (3) EP2283858A3 (en)
JP (2) JP4718778B2 (en)
KR (2) KR20040028952A (en)
CN (2) CN1935258B (en)
AU (1) AU2002365244B2 (en)
BE (1) BE2014C006I2 (en)
BR (1) BRPI0211492B1 (en)
CA (1) CA2452545C (en)
CY (1) CY2014010I1 (en)
DK (1) DK1427444T3 (en)
ES (1) ES2435095T3 (en)
FR (1) FR14C0016I2 (en)
HK (1) HK1066470A1 (en)
HR (1) HRP20040195B1 (en)
HU (2) HU228690B1 (en)
LU (1) LU92348I2 (en)
ME (1) ME00491B (en)
MX (1) MXPA04000680A (en)
NZ (3) NZ531265A (en)
PL (2) PL220846B1 (en)
PT (1) PT1427444E (en)
RS (1) RS53184B (en)
WO (1) WO2003061555A2 (en)
ZA (1) ZA200401596B (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7425437B2 (en) * 1999-11-26 2008-09-16 Crucell Holland B.V. Vaccines against West Nile Virus
CN1935258B (en) * 2001-07-27 2013-04-03 惠氏公司 West nile vaccine
US7585621B2 (en) * 2003-09-09 2009-09-08 Idexx Laboratories, Inc. Detection of West Nile virus infection and vaccination
US7074555B2 (en) * 2004-04-28 2006-07-11 Idexx Laboratories, Inc. Detection of West Nile Virus
FR2870126B1 (en) 2004-05-17 2009-07-17 Pasteur Institut RECOMBINANT LENTIVIRAL VECTOR FOR EXPRESSION OF FLAVIVIRIDAE PROTEIN AND ITS APPLICATIONS AS VACCINE
WO2006029300A2 (en) 2004-09-09 2006-03-16 Research Development Foundation Flavivirus variants having phenotypic variation and immunogenic compositions thereof
AU2006232865A1 (en) * 2005-04-01 2006-10-12 Wyeth Use of WNV DNA vaccine in combination with a conventional vaccine to overcome immunogen interference
US11865172B2 (en) 2005-04-21 2024-01-09 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
AU2006245734C1 (en) 2005-05-12 2012-05-24 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
WO2006122964A1 (en) * 2005-05-19 2006-11-23 Crucell Holland B.V. Methods for the production of a whole-inactivated west nile virus vaccine
EP1724338A1 (en) * 2005-05-19 2006-11-22 Crucell Holland B.V. Methods for the production of a whole-inactivated West Nile Virus vaccine
NZ564375A (en) 2005-06-24 2010-02-26 Intervet Int Bv Inactivated chimeric flavivirus vaccines and related methods of use
NO346351B1 (en) * 2005-10-19 2022-06-20 Intervet Int Bv Isolated Canine Influenza Avirus, Polynucleotide Expression Construct, Isolated Antibody, Isolated Cell, Reassortant Virus and Recombinant Virus Vector, and Composition and Canine Influenza Vaccine
WO2007047728A2 (en) * 2005-10-20 2007-04-26 Wyeth Compositions and methods for the treatment of canine influenza virus disease
WO2007094854A2 (en) * 2005-12-14 2007-08-23 The Board Of Regents Of The University Of Oklahoma Rna virus vaccines and methods
SI2395018T1 (en) 2006-06-06 2016-06-30 Crucell Holland B.V. Human binding molecules having killing activity against staphylococci and uses thereof
CN101883581A (en) * 2007-11-06 2010-11-10 惠氏有限责任公司 Mycoplasma hyopneumoniae avirulent adjuvanted live vaccine
US9415006B2 (en) 2008-05-23 2016-08-16 The Regents Of The University Of Michigan Immunogenic compositions comprising nanoemulsion and hepatitis B virus immunogen and methods of using the same
EP2306812A4 (en) * 2008-07-30 2013-02-20 Univ Kentucky Res Found Equine disease model for herpesvirus neurologic disease and uses thereof
SG193821A1 (en) 2008-08-29 2013-10-30 Boehringer Ingelheim Vetmed West nile virus vaccine
EP2485725A2 (en) * 2009-10-07 2012-08-15 Wyeth LLC Compositions comprising adjuvant, macrolide and proteinaceous antigen and methods of use thereof
WO2012125525A2 (en) 2011-03-14 2012-09-20 Boehringer Ingelheim Vetmedica, Inc. Equine rhinitis vaccine
CN103045544B (en) * 2011-10-17 2015-01-14 华中农业大学 Recombinant pseudotyped baculovirus Bac-G-prM/E for preventing West Nile virus as well as vaccine and application thereof
AU2014265649B2 (en) * 2013-05-14 2017-10-19 Zoetis Services Llc Novel vaccine compositions comprising immunostimulatory oligonucleotides
AU2014315353A1 (en) * 2013-09-05 2016-03-10 Zoetis Services Llc Hendra and Nipah virus G glycoprotein immunogenic compositions
US11033615B2 (en) 2016-05-31 2021-06-15 The Government of the United States, As Represented by the Secretary of the Army Fort Detrick, Maryland Zika virus vaccine and methods of production
PL70842Y1 (en) * 2017-08-25 2019-06-28 Gondek Lukasz Kuznia Mocy Device for regeneration of solid particles filters and automobile analytic converters
US20220133877A1 (en) 2019-02-27 2022-05-05 University Of Rochester Multivalent Live-attenuated Influenza Vaccine for Prevention and Control of Equine Influenza Virus (EIV) in Horses

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US308334A (en) 1884-11-18 Ladder
US6184024B1 (en) 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
US5741696A (en) * 1992-08-07 1998-04-21 Syntro Corporation Recombinant equine herpesviruses
FR2702373B1 (en) * 1993-03-08 1996-06-07 Rhone Merieux Water-in-oil fluid vaccine emulsions containing a metabolizable oil.
EP0968722B1 (en) * 1994-05-10 2007-06-20 Wyeth Improved modified live BRSV vaccine
US7227011B2 (en) 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
WO1999063095A1 (en) 1998-06-04 1999-12-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nucleic acid vaccines for prevention of flavivirus infection
US20020164349A1 (en) 2000-10-04 2002-11-07 Weiner David B. Compositions and methods of using capsid protein from Flaviviruses and Pestiviruses
WO2002068637A2 (en) 2000-10-20 2002-09-06 Ribozyme Pharmaceuticals, Inc. Nucleic acid-based treatment of diseases or conditions related to west nile virus infection
AU2002305028A1 (en) 2001-02-28 2002-10-28 Brown University Research Foundation West nile virus epitopes and uses thereof
WO2002072036A2 (en) * 2001-03-12 2002-09-19 Yale University Compositions and methods comprising west nile virus polypeptides
US20030104008A1 (en) * 2001-04-06 2003-06-05 Loosmore Sheena May Recombinant vaccine against west nile virus
FR2823222B1 (en) * 2001-04-06 2004-02-06 Merial Sas VACCINE AGAINST NILE FEVER VIRUS
CN1935258B (en) * 2001-07-27 2013-04-03 惠氏公司 West nile vaccine
US7785799B2 (en) 2002-08-16 2010-08-31 The Board Of Regents Of The University Of Texas System Compositions and methods related to flavivirus envelope protein domain III antigens

Also Published As

Publication number Publication date
CY2014010I1 (en) 2020-05-29
HRP20040195A2 (en) 2004-08-31
BE2014C006I2 (en) 2021-02-04
MXPA04000680A (en) 2004-04-05
RS53184B (en) 2014-06-30
EP2281572A1 (en) 2011-02-09
LU92348I9 (en) 2019-01-02
CN1535157A (en) 2004-10-06
HUP0401606A3 (en) 2005-02-28
HUS1300055I1 (en) 2016-08-29
CN1935258B (en) 2013-04-03
US20070178119A1 (en) 2007-08-02
CN1273189C (en) 2006-09-06
WO2003061555A3 (en) 2004-04-15
PT1427444E (en) 2013-11-19
HK1066470A1 (en) 2005-03-24
DK1427444T3 (en) 2013-11-04
JP4718778B2 (en) 2011-07-06
PL220846B1 (en) 2016-01-29
EP2283858A3 (en) 2011-03-23
US7648706B2 (en) 2010-01-19
KR20040028952A (en) 2004-04-03
PL398575A1 (en) 2012-06-18
US7445787B2 (en) 2008-11-04
HUP0401606A2 (en) 2004-11-29
US20070166326A1 (en) 2007-07-19
PL368535A1 (en) 2005-04-04
US20070166324A1 (en) 2007-07-19
HRP20040195B1 (en) 2014-07-18
CA2452545C (en) 2015-06-09
EP2283858A2 (en) 2011-02-16
US20070166802A1 (en) 2007-07-19
CA2452545A1 (en) 2003-07-31
FR14C0016I1 (en) 2014-03-28
US20070231349A1 (en) 2007-10-04
PL212212B1 (en) 2012-08-31
US7153513B2 (en) 2006-12-26
LU92348I2 (en) 2014-09-22
CN1935258A (en) 2007-03-28
US7648705B2 (en) 2010-01-19
NZ553165A (en) 2008-09-26
ME00491B (en) 2011-10-10
US20070231350A1 (en) 2007-10-04
AU2002365244B2 (en) 2007-12-06
KR20090053967A (en) 2009-05-28
NZ531265A (en) 2008-08-29
JP2011057692A (en) 2011-03-24
ZA200401596B (en) 2005-07-27
HU228690B1 (en) 2013-05-28
BR0211492A (en) 2004-08-17
NZ570270A (en) 2010-08-27
YU8004A (en) 2006-08-17
US20030091595A1 (en) 2003-05-15
EP1427444A4 (en) 2008-01-02
EP1427444A2 (en) 2004-06-16
EP1427444B1 (en) 2013-08-21
WO2003061555A2 (en) 2003-07-31
BRPI0211492B1 (en) 2016-06-21
JP2005515236A (en) 2005-05-26
ES2435095T3 (en) 2013-12-18
US20070166325A1 (en) 2007-07-19

Similar Documents

Publication Publication Date Title
FR14C0016I2 (en) WEST NILE VACCINE
LU93048I2 (en) PROTEQ WEST NILE
ATE553775T1 (en) VACCINE COMPOSITION
NO20031483D0 (en) Vaccine
ATE420159T1 (en) FLU VACCINE COMPOSITION
NO20034683D0 (en) Intradermal vaccine device
DE60239828D1 (en) ÜR
NO20024172D0 (en) Vaccine
IS7291A (en) Marked kirni
NO20030823D0 (en) vaccinations
NO20026175L (en) vaccine Composition
NO20031705D0 (en) vaccinations
IS7297A (en) Streptococcis Pneumoniae vaccine
IS7831A (en) vaccine
NO20033882D0 (en) Vaccine
DE60328408D1 (en) VACCINE
NO20051561D0 (en) Vaccine
NO20034165D0 (en) anchoring sleeve
DE10290185D2 (en) tumor vaccine
SE0100410D0 (en) Retaining
SE0103470D0 (en) Retaining
SE0103415D0 (en) Retaining
FI5103U1 (en) Floorball Club
NO20011990D0 (en) cancer vaccine
NO20012126D0 (en) HIV vaccine